准分子伴侣CCT2通过影响KRAS稳定性来抑制GBM进展
Feihu Zhao1, Zhong Yao2, Yaquan Li1
1Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, 250012, PR China; Jinan Microecological Biomedicine Shandong Laboratory and Shandong Key Laboratory of Brain Function Remodeling, Jinan, 250017, PR China.
这项研究表明,CCT2蛋白通过稳定KRAS.促进质母细胞瘤. 乙甲美西宁通过准CCT2和KRAS信号通路,有效治疗质母细胞瘤.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 神经科学是一个神经科学.
背景情况:
- 蛋白质错误折叠和伴侣功能障碍与癌症等疾病有关.
- CCT2是已知的伴侣子单元和自受体,但其在质母细胞瘤中的作用尚不清楚.
研究的目的:
- 研究CCT2在质母细胞瘤进展中的作用.
- 确定针对质母细胞瘤中CCT2和KRAS信号的治疗策略.
主要方法:
- 共同免疫沉,质谱和表面等离子体共振被用来分析CCT2-KRAS相互作用.
- 用质母细胞瘤动物模型来评估二甲美西宁的治疗效果.
- 使用CCT2过度表达来验证其在药物耐药性中的作用.
主要成果:
- CCT2直接与KRAS结合,增强其稳定性和下游信号,从而促进质母细胞瘤.
- 二甲胺素直接与CCT2结合,并通过减少KRAS信号来抑制质母细胞瘤的进展.
- 过度表达CCT2抵消了二甲米西宁的抑制作用,证实了CCT2的关键作用.
结论:
- 通过稳定KRAS,CCT2促进质母细胞瘤,从而呈现出治疗点.
- 乙甲胺素通过向CCT2-KRAS轴,克服KRAS"无药性",为质母细胞瘤提供了潜在的治疗方法.
更多相关视频
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inhibition of Cdk Activity
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
The Ras Gene
Ras is a...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
